На основании изучения текстов инструкций для медицинского применения 8 торговых марок Небиволола установлено наличие разночтений в некоторых разделах исследуемых текстов. Полученные результаты подтверждают асимметричность информации о фармакологической идентичности лекарств-аналогов, а также необходимость учитывать коммуникативные расхождения инструкций для медицинского применения лекарств-аналогов с целью обеспечения безопасного назначения пациентам лекарственных средств и уменьшения проблем, связанных с лекарствами вследствие их применения.
8 instructions for medical used trademarks of Nebivolol in tablets of 5 mg, which are included in the State Register of drugs on 27.04.2013. There were used contextual and qualitative analysis of the text It is established that the active ingredient of the drug-analogues is nebivolol hydrochloride. However, the analyzed drugs differ in name and number additional substances affecting the stability and effectiveness of drugs for some time.
In the analyzed instructions for medical use there were revealed discrepancies regarding indications and contraindications, adverse reactions and expiratory date of drugs-analogous Information about medical use of drugs studied by children and women during pregnancy and lactation has also some discrepancies.
Conclusions. Based on a comparative study of instructions for medical used 8 trademarks of Nebivolol there were established significant discrepancies in some sections of the text studies. The result of this communicative differences may become inadequate perception of instructional text for medical use, which will result in taking the wrong drugs and drug related problems. The results obtained confirm the asymmetry of information about the pharmacological identity of drugs-analogues without prooving bioequivalence data. Doctors should take into consideration the problem of communicative differences in instructions for medical use of the drugs-analogues to ensure safe administration and use of drugs.
